One group noted the expression of FXR was downregulated in MS patients, more so in PPMS than RRMS patients and an in vivo treatment with FXR agonist GW4064 yielded significant diminished inflammatory markers when compared to vehicle-treated mice. Here, NR1H4 is linked to myeloid sarcoma.